Linagliptin treating diabetes after liver transplantion

Linagliptin treating diabetes after liver transplantion: randomized controlled clinical trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17010537

Enrollment

Unknown

Registered

2017-02-01

Start date

2017-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

transplant recipient, diabetes

Interventions

Linagliptin group:Linagliptin

Insulin group:HumalogMix50

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diabetes after liver transplantion; 2. To be aged 18 years and more; 3. Diet and exercise control more than eight weeks, HbA1c from 7.0% to 10.0%; 4. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Diabetes before liver transplantion; 2. Biliary obstruction or intestinal obstruction; 3. History of pancreatitis; 4. Into the group occurred within 6 months before myocardial infarction, stroke, or transient ischemic attack; 5. Brain disease, abnormal judgement ability; 6. Mental disease, malignant tumor, active TB patients; 7. Drugs and/or alcohol abuse; 8. Allergic to test drugs or composition; 9. Pregnancy or lactation; 10. One month before the start of this research, participated in any clinical research test drugs; 11. Not suitable for clinical trials because of other reasons.

Design outcomes

Primary

Measure	Time frame
HbA1c;	—

Secondary

Measure	Time frame
Blood glucose;	—

Countries

China

Contacts

Public ContactXu Chun

The General Hospital of Chinese People's Armed Police Forces

wjxuchun@sohu.com+86 10 57976568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026